Where the Longevity Industry Is Today | The Longevity Equation – Chapter 1

For generations, the dream of “living longer” has been shared by many and has mainly floated nebulously between myth and evidence-based medicine. Today, the pursuit of longevity has birthed a legitimate scientific field, an economic force projected by UBS to reach $7.8 trillion by 2030, and, perhaps most importantly, a tremendous opportunity for the widespread improvement of public health. Yet, there’s still confusion about what “longevity” actually means, and how close we are to meaningful breakthroughs.

This first chapter in our new Spotlight: Longevity in Context (SLIC) series, The Longevity Equation, is meant to build upon what all our SLIC pieces have done in the past: offering a clear, unbiased reflection on where longevity truly stands today, and begin a broader conversation that will continue in the chapters to follow. Before exploring the most promising novel research, spotlighting innovators, or handing over the “key” to longevity, which everyone is after, we need to understand the goal and definition of longevity. What are we actually trying to achieve, and how are a wide array of actors shaping the future?

This chapter is not an argument for one framework of longevity over another, nor an attempt to downplay or elevate any particular vision of the future. The longevity field contains multiple schools of thought, from those focused on extending healthspan by adding more years of good, functional health to those pushing for radical lifespan extension or even the elimination of aging altogether. Each perspective contributes something incredibly valuable to the community. Our aim here is not to take sides in what remains a diverse and evolving conversation but simply to map the landscape for consumers, biohackers, curious explorers, investors, policymakers, medical professionals, and anyone trying to make sense of longevity today, and highlight where the space stands today.

When most people hear “longevity,” they picture extreme lifespans, like living to 120, 150, maybe beyond. This is in part true - some researchers in the scientific community are actively pursuing radical life extension, exploring ways to slow or stop aging so dramatically that human lifespan could increase by decades or more. Meanwhile, a fast-growing consumer-facing movement focuses on lifestyle-driven improvements like nutrition, sleep, exercise, and supplements to live the “optimized” life now.

What’s also true for many clinicians, public-health experts, and biologists is that the meaning of “longevity” has evolved into something a bit broader.

Is the true endpoint more years, more years in better health, or a combination of the two? At the LSF, we drive toward a world where populations remain healthy, independent, and mentally sharp for far longer than today’s norms - a world where longevity means compressing the years of poor health into a much smaller portion of life, or ideally eliminating them altogether. Where chronic diseases can be predicted early, prevented proactively, and treated more precisely. Where the experience of aging changes from inevitable decline to something more like sustained enjoyment of life in later years, free from many of the physical, mental, emotional, and economic burdens that so often accompany aging today. Doing so holistically, accessibly, and equitably as a right for all instead of a privilege for the few, and as a byproduct of living far longer as human beings.

If we can reach a point where most people maintain physical and cognitive vitality into their 80s, 90s, or beyond, then we’ve largely succeeded. Radical extensions of lifespan may follow, but the first unmet need remains the radical extension of healthspan.

Over the past decade, the language around aging has changed dramatically. Lifespan, as used across gerontology and demographic research, refers to the total number of years someone lives. In contrast, healthspan, a term increasingly used in preventive medicine, refers to the number of years lived in good health, free from chronic disease, functional decline, and the loss of independence.

Today, the average person in a high-income country spends 10-20 years in a state of poor health – a pattern documented by the World Health Organization, the OECD, and the Global Burden of Disease study [1-3]. These years are often marked by diabetes, cardiovascular disease, dementia, frailty, and reduced independence. This means that for many, noticeable decline begins in the late 50s, with chronic diseases accumulating through the 60s. Longevity science aims to close that gap.

This shift in framing and focus on these two ideologies represents a fundamental change from the traditional “sick care” health economy, a model that has frustrated and underserved so many, and is in part responsible for the birth of the longevity ecosystem. A new landscape, sometimes called the preventive health economy or “Medicine 3.0”, is emerging. This ecosystem prioritizes:

Longevity is not a departure from traditional healthcare, rather its much-needed extension. At its core, longevity science asks the same questions traditional medicine always has: How do we prevent disease, preserve function, and keep people thriving for as long as possible? The difference is that longevity prioritizes early optimization and risk reduction - something our current “sick care” systems, which primarily react to disease once it appears, rarely deliver at scale. Today, new tools allow us to look deeper into the biological processes that drive aging itself, revealing shared mechanisms across multiple chronic diseases and opening the door to a truly preventive framework. This shifts longevity from a niche aspiration to a broader, systems-level approach to health, spanning everything from cellular repair and metabolic resilience to brain health, immunity, reproductive aging, and whole-body performance. In other words, longevity is simply the next chapter in the evolution of healthcare, moving from treating illnesses once they’ve happened to maintaining health early and continuously. This shift has attracted attention not only from scientists but also from governments, philanthropists, investors, and biotech innovators.

The longevity industry is not a single discipline, but rather a sprawling ecosystem. To understand where we are today, it helps to map out the major players:

These are the brilliant minds driving foundational discoveries in the biology of aging, chronic and age-related diseases, and predictive/preventive health by uncovering new mechanisms, creating scientific models, and developing tools for measuring biological age, the internal wear-and-tear that isn’t visible on a calendar.

Academic centers leading this work span the globe, from the Centre for Healthy Longevity in Singapore to the Buck Institute in California, the Max Planck Institute in Germany, and aging research hubs at universities like Copenhagen, Oxford, Stanford, and King’s College in London. Beyond these flagship institutes, countless universities house labs across departments, from molecular biology to neuroscience, women’s health, and even exercise physiology, that all contribute to longevity science.

But academia does more than generate discoveries; it seeds the entire longevity innovation pipeline. Many of today’s most promising companies began as spin-offs from academic labs, where foundational work on cellular aging, senescence, epigenetic reprogramming, biomarkers, and chronic disease mechanisms first took shape. As these discoveries mature, academic technology-transfer offices (TTOs) help translate them into patents, launch spin-out ventures, and connect researchers with industry partners. This process forms the bridge between fundamental insights and real-world solutions, enabling longevity technologies to become focused, clinically relevant, and ultimately capable of reaching patients.

Innovation begins in academia, cementing early-stage research as a catalyst for unlocking new developments in longevity, which the world yearns to discover. It’s also the stage that is most critically underfunded due to the lack of immediate commercial applicability or financial ROI. But, as mentioned, translating research from bench to bedside often requires follow-on resources well beyond the scope of academic grants, demanding coordination across funders, institutions, and industry partners.

Although governments have historically underestimated the economic and societal impact of aging, that’s beginning to change. In many industrialized countries, the ratio of retirees to working-age adults is rising rapidly; for example, according to the OECD, the share of people aged 65+ in high-income countries has risen from about 21% of the working-age population in the 1990s to around 33% in 2024, and it’s projected to reach roughly 55% by 2060. Most population-wide early detection and pre-screening programs, though often under-resourced, low-retention, or inconsistently implemented, are still state-mandated, underscoring that governments already acknowledge the need for early intervention, even if current systems fall far short of what aging populations require.

Against this backdrop, public health and long-term-care spending are set to climb. OECD and World Bank analyses estimate that health spending alone could reach ~8.6% of GDP by 2040 in these countries, which could mean an extra $40–50 billion or more annually.

Still, the gap between public need and public investment remains large. Modelling suggests that increased tax revenue will cover only about a quarter of the anticipated rise in pension spending. As labor supply shrinks and healthcare demands grow, the economic imperative for preventive, aging-focused strategies becomes clear.

Around the world, several governments are now recognizing that aging populations require proactive investment rather than reactive spending. Japan, the most rapidly aging nation globally, has launched extensive initiatives in geroscience, robotics for aging care, and early-detection health programs. The United Kingdom has committed to adding five extra healthy years to national life expectancy by 2035 and is funding aging-biology research through the UKRI and ARIA agencies. Saudi Arabia, through the Hevolution Foundation, has become one of the world’s largest supporters of longevity science, aiming to accelerate breakthroughs in aging biology and preventive medicine. Across the European Union, initiatives in countries like Estonia, Denmark, Germany, and Switzerland are expanding national strategies around healthy aging, early-stage biotech support, and digital health innovation.

Together, these efforts reflect a broader shift where longevity is seen as a national priority for economic stability, quality of life, and long-term health sustainability.

This includes foundations and not-for-profits like the LSF, which step in where traditional funding does not, often because early-stage longevity research is seen as too risky, too new, or too uncertain to attract conventional grants or investment. Philanthropy plays a key role in:

Many breakthroughs in aging science, from senolytics to biomarker development, originated from philanthropic support.

Philanthropic activity in longevity isn’t just about writing grants; it’s also about activating donor communities. Mobilizing individuals, family offices, and mission-driven funders to put real dollars behind science can radically accelerate progress and help move research to the stage where commercial investment becomes both de-risked and appropriate. When donors understand the stakes and the potential impact, they become catalysts, bringing private capital and long-term commitment to a field that has historically been under-resourced. This ignition of private support is often what transforms early scientific promise into transformative, real-world change.

Once an idea gains traction, private capital helps turn it into a therapy, product, or technology. In the past five years, the field has seen an explosion of venture-backed biotechs translating aging science into real interventions. Companies like Retro Biosciences, which is advancing cellular reprogramming and plasma-based rejuvenation therapies, and Rubedo Life Sciences, now in first-in-human trials with senescent-cell–targeting therapeutics, are emblematic of this momentum. In the same vein, Calico, Google’s aging research company, launched in partnership with AbbVie, continues to invest heavily in understanding the mechanisms of aging and developing therapies for age-related diseases, while Altos Labs, a $3 billion venture funded by Jeff Bezos, is pursuing cellular rejuvenation at scale.

Equally important, but often less visible, are the enabling technologies that make longevity therapeutics possible. AI-driven discovery platforms, computational chemistry engines, large-scale biological databases, and high-throughput screening technologies are dramatically accelerating the pace of drug development. Companies like Insilico Medicine exemplify this shift: its AI-first platform has already produced multiple preclinical candidates and advanced one into human trials for fibrosis, showcasing how computational tools can compress timelines and diversify the pipeline for longevity-focused therapeutics. As the field matures, these platforms may determine how quickly we can generate interventions with a true longevity dividend.

Meanwhile, the industry is also seeing hints of what systemic healthspan improvement may look like at scale. GLP-1 receptor agonists, initially developed for diabetes and weight management, are demonstrating wide-ranging benefits on metabolic health, inflammation, cardiovascular risk, and liver function. Recent discussions at ARDD, one of the leading annual conferences on aging research and therapeutics, highlighted that GLP-1s may offer the first real-world example of a single intervention influencing multiple aging-related pathways simultaneously.

Large pharmaceutical companies are keenly eyeing the field, often partnering with academic groups or acquiring early startups once results look promising. Eli Lilly has invested in senescence research focusing on eliminating the aging cells that stop dividing but remain active and harmful. Roche and Genentech are expanding biomarker and early-detection efforts, while AstraZeneca and Johnson & Johnson are working with AI and regenerative medicine companies that target aging pathways.

Wearable technology, nutritional interventions, and personalized health tools have accelerated the spread of longevity science beyond the lab. They’ve given millions of people access to real-time data on sleep, activity, heart rate variability, glucose responses, and other early indicators of health, something that would have been unthinkable a decade ago.

Consumers play an essential role in this ecosystem. They create demand, signaling to researchers, funders, and companies that prevention and proactive health matter. Their engagement generates massive amounts of real-world data, helping the industry understand patterns that are impossible to capture in clinical trials. Just as importantly, the presence of a large consumer audience forces longevity science to speak a more accessible, human language. Companies and, increasingly, researchers, must translate complex biology into concepts people can understand and act on. In doing so, the field becomes more democratized: longevity is no longer an abstract scientific pursuit but something ordinary people can learn about, engage with, and apply to their daily lives.

Yet, open consumer markets also bring challenges. Products often move faster than evidence. Some tools overpromise or rely on limited or early data. Accessibility varies widely, and without clear standards, the gap between what is scientifically sound and what is marketed can widen quickly.

Still, the consumer side of longevity has become a powerful force, broadening awareness, accelerating early adoption, and pushing the entire field to communicate more clearly and inclusively than ever before.

At the LSF, we believe longevity is fundamentally about better health outcomes powered by rigorous science for all, because aging is universal. Every population faces rising rates of chronic disease, disability, and healthcare costs. Some, particularly LMICs, women, and people of color experience a combination of those pressures at significantly elevated levels. If only a small group benefits from longevity advances, we haven’t come close to solving the core problem; we’ve simply created a new inequality. “For all” means making longer, healthier lives accessible, affordable, and grounded in evidence, not privilege.

We support research that:

Aging biology touches nearly every major disease: cancer, cardiovascular disease, neurodegeneration, metabolic dysfunction, reproductive aging, and more. By addressing shared underlying mechanisms, we can improve outcomes across multiple conditions at once.

This systems-level view is at the heart of our approach. Longevity is not about treating aging as an isolated target but about changing how we approach health at every point in life.

The early-stage pipeline of longevity research is crowded with ideas but starved of resources. This is exactly where we operate, and look to partner to create radical, exponential impact.

We act as a catalyst. We identify high-potential scientific ideas that lack early funding. We help researchers cross the “valley of death”, the stage where promising concepts often stall before they can produce data, attract partners, or move toward translation. This support is especially critical for teams working in underfunded institutions or smaller research groups, where groundbreaking ideas often exist but lack the resources, visibility, or infrastructure needed to advance.

We act as a truth broker. With so much hype, conflicting information, and marketing-heavy claims in longevity, the public is often unsure what to believe. We help people understand what’s real, what’s emerging, what’s overhyped, and what’s still far off. Education is one of our core responsibilities, which is why we created series like Hype vs Reality and Spotlight: Longevity in Context.

We act as a researcher reliever. Scientists are often overwhelmed by administrative burdens, fundraising challenges, and limited time. We step in to reduce friction, supporting them so they can focus on what matters the most.

We act as a turnkey for innovation. When we support a project, we don’t just write a check. We provide guidance, community, visibility, and a path toward scaling. We help transform early ideas into real-world impact.

Philanthropy has an outsized effect on longevity: a single seed grant can unlock a cascade of scientific and economic progress. Many of today’s breakthroughs were once just early, risky ideas. Our mission is to make sure the next generation of breakthroughs doesn’t get left behind.

We stand at a pivotal moment. The science of longevity is progressing rapidly, but the translation of that science into public health benefits is far from guaranteed. If we want a future where people truly live healthier for longer, regardless of income, geography, or status, then the field must be guided by:

That is what the LSF exists to protect and accelerate. We welcome partners who want to help accelerate this mission; reach out to explore how your support can catalyze the next generation of longevity breakthroughs.